Journal of Clinical & Experimental Pathology
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
To develop an effective population based screening programme for cervical cancer detection as there is a lack of effective
organised screening programs for cervical cancer.
Cervical Cancer (Cervix Uteri) is the most common form of Cancer among women in India. India has a population of
366.58 million women ages 15 years and older who are at risk of developing cervical cancer. Cervical cancer ranks as the 1st
most frequent cancer among women in India. Current estimates indicate that every year 134,420 women are diagnosed with
cervical cancer and 72,825 die from the disease. Cervical cancer has the highest rate of cancer incidence & mortality among
Cancer starts with infection with HPV and then persistence of infection leads onto preinvasive lesion and after 10-15
years into invasive cervical cancer. The development of cervical cancer is typically slow, and occurs over a period of years. The
progression to cervical cancer begins with the development of precancerous changes in normal cells. Most of these changes,
even if left untreated, will not progress to cancer.
There are several risk factors for the development of cervical cancer, both genetic and environmental. These include: Human
Papillomavirus (HPV) Infection, Family History of Cervical Cancer, Age, Sexual and Reproductive History, Socioeconomic
Status, Smoking, HIV Infection, long-term use of oral contraceptives, >99% of Cervical Cancer cases are attributed to HPV
infection - World Cancer Congress 2012.
Although cancer of the cervix can develop in women of all ages, it usually develops in women aged 35-55 years, with the
peak age for incidence varying with populations (Zeller et al, 2007). In India, the peak age for cervical cancer incidence is 45-54
years, which is similar to the rest of South Asia [WHO/ICO Information Centre on HPV and Cervical Cancer (a)].
Manu Noatay is Laboratory Director and Principal Consultant, Niche Theranostics and Co- founder of Niche Foundation, Lab Medicine Expert (M.B.B.S.) & (M.D.)
with rich experience in Medical/laboratory Operations and Clinical Research. Dr. Manu Noatay is a Keen Cytopathologist and currently working with various
agencies like FPAI, FOGSI and Parivar Sanstha along with key opinion leaders in Gynecology in field of cervical pre-cancer detection with help of latest FDA
approved technologies. She has completed her M.D. (Pathology) from Army Hospital Research & Referral, New Delhi (Delhi University), M.B.B.S. from I.G.M.C.,
Shimla (H.P. University). Fellowship of International Academy of Cytology. She is also a Member of IAPM, Member of British Society of Clinical Cytology, Fellow
of International Academy of Cytopathology and Renal Pathology Society. Dr. Manu Noatay has wide range of experience as lab medicine expert in Apollo Clinics,
Fortis Escorts and Super Religare Laboratories in past, mainly as Chief of Pathology for past 8 years. She has published papers and Presented poster and
conducted workshop in various international Conferences.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals